• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Probable leucine–tRNA ligase, mitochondrial (LARS2), Truncated

ACP18456

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP18456 Target NameLARS2
Target Synonymsmitochondrial; SYLM_HUMANFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ15031
Background Information
  • Uniprot Id

    Q15031

  • Target Species

    Human

  • Target Name

    LARS2

  • Target Full Name

    Leucine--tRNA ligase, mitochondrial

  • Target Involvement

    Perrault syndrome 4 (PRLTS4); Hydrops, lactic acidosis, and sideroblastic anemia (HLASA)

  • Target Subcellular Location

    Mitochondrion matrix.

  • Target Protein Families

    Class-I aminoacyl-tRNA synthetase family

  • Target Tissue Specificity

    Ubiquitously expressed, but highest expression in tissues with high metabolic rates, such as skeletal muscle, heart, and kidney.

  • Target Synonyms

    HLASA; KIAA0028; LARS 2; Lars2; Leucine translase; Leucine tRNA ligase 2; Leucine tRNA ligase 2 mitocondrial; Leucine tRNA ligase; Leucine--tRNA ligase; Leucyl tRNA synthetase 2; Leucyl tRNA synthetase 2 mitochondrial; LeuRS; MGC26121; mtLeuRS; PRLTS4; Probable leucyl-tRNA synthetase, mitochondrial; SYLM_HUMAN

Inquire Recombinant Human Probable leucine–tRNA ligase, mitochondrial (LARS2), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification